Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Achieving high efficiency, targeted gene delivery with adenoviral vectors is a long-standing goal in the field of clinical gene therapy. To achieve this, platform vectors must combine efficient retargeting strategies with detargeting modifications to ablate native receptor binding (i.e. CAR/integrins/heparan sulfate proteoglycans) and “bridging” interactions. “Bridging” interactions refer to coagulation factor binding, namely coagulation factor X (FX), which bridges hepatocyte transduction in vivo through engagement with surface expressed heparan sulfate proteoglycans (HSPGs). These interactions can contribute to the off-target sequestration of Ad5 in the liver and its characteristic dose-limiting hepatotoxicity, thereby significantly limiting the in vivo targeting efficiency and clinical potential of Ad5-based therapeutics. To date, various approaches to retargeting adenoviruses (Ad) have been described. These include genetic modification strategies to incorporate peptide ligands (within fiber knob domain, fiber shaft, penton base, pIX or hexon), pseudotyping of capsid proteins to include whole fiber substitutions or fiber knob chimeras, pseudotyping with non-human Ad species or with capsid proteins derived from other viral families, hexon hypervariable region (HVR) substitutions and adapter-based conjugation/crosslinking of scFv, growth factors or monoclonal antibodies directed against surface-expressed target antigens. In order to maximize retargeting, strategies which permit detargeting from undesirable interactions between the Ad capsid and components of the circulatory system (e.g. coagulation factors, erythrocytes, pre-existing neutralizing antibodies), can be employed simultaneously. Detargeting can be achieved by genetic ablation of native receptor-binding determinants, ablation of “bridging interactions” such as those which occur between the hexon of Ad5 and coagulation factor X (FX), or alternatively, through the use of polymer-coated “stealth” vectors which avoid these interactions. Simultaneous retargeting and detargeting can be achieved by combining multiple genetic and/or chemical modifications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“The design of such vectors exploits the knowledge that tumor cells frequently possess dysfunctional, or non-functional pRb tumor suppressor proteins [101].”
BackgroundOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis
Leopold, P. L., Kreitzer, G., Miyazawa, N., Rempel, S., Pfister, K. K., Rodriguez-Boulan, E., & Crystal, R. G. (2000) · Human Gene Therapy · doi:10.1089/10430340050016238 · Cited by 254 · cited 2×
“Transport to the nuclear pore complex involves the microtubule-dependent motor, cytoplasmic dynein, which facilitates Ad attachment to microtubules [45,46].”
BackgroundMacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., & Esko, J. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29154 · Cited by 216
Shi, Y., Chen, C., Lisewski, U., Wrackmeyer, U., Radke, M., Westermann, D., Sauter, M., Tschöpe, C., Poller, W., Klingel, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.064 · Cited by 112
Cited by
Heparan sulfate proteoglycan as a cell-surface endocytosis receptor
Christianson, H. C., & Belting, M. (2014) · Matrix Biology · doi:10.1016/j.matbio.2013.10.004 · Cited by 429
“Strategies to retarget adenoviruses include genetic modifications to incorporate peptide ligands directed against alternative target cell surface antigens simultaneously with genetic or chemical ablation of native, HSPG-binding determinants (Coughlan et al., 2010).”
Recent advances of oncolytic virus in cancer therapy
Mondal, M., Guo, J., He, P., & Zhou, D. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1723363 · Cited by 224
Adenoviruses as gene/vaccine delivery vectors: Promises and pitfalls
Appaiahgari, M. B., & Vrati, S. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.993374 · Cited by 110
“To this end, development of chimeric viruses expressing ligands of other Ad serotypes with different cell type specificities have been shown to demonstrate altered tropism both in vitro as well as in vivo [67,70,71].”
BackgroundInfluentialAlbumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery
Rojas, L. A., Condezo, G. N., Moreno, R., Fajardo, C. A., Arias-Badia, M., San Martín, C., & Alemany, R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.004 · Cited by 66
Circumventing Antivector Immunity: Potential Use of Nonhuman Adenoviral Vectors
Lopez-Gordo, E., Podgorski, I. I., Downes, N., & Alemany, R. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.228 · Cited by 65
Valsalakumari, J., Baby, J., Bijin, E., Constantine, I., Manjila, S., & Pramod, K. (2013) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.108958 · Cited by 48
Metadata
- Authors
- Coughlan, L., Alba, R., Parker, A. L., Bradshaw, A. C., McNeish, I. A., Nicklin, S. A., & Baker, A. H.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2010-10-13
- Volume
- 2
- Issue
- 10
- Pages
- 2290-2355
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W1983966759
- Cited by
- 120
- References
- 5
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.